摘要
Abstract
Objective To investigate the effect and safety of recombinant tissue plasminogen (rtPA) combined with urokinaseon in treatment of acute cerebral infarction. Methods 129 patients who received thrombolytic therapy in our hospital from November 2005 to December 2012 were selected,and were divided into rtPA group (63 cases) and rtPA combined with urokinaseon group (66 cases).The demographic data,onset-to-needle time and baseline clinical charac-teristics (symptoms,medical history,blood pressure,blood glucose,blood lipids,National Institutes of Health Stroke Scale (NIHSS) score,Barthel index (BI) were recorded at baseline.The NIHSS and BI were recorded at 7 days,30 days and 90 days after thrombolysis.The mortality rate and theincidences of intracerebral and other hemorrhages were recorded. Re-sults After intravenous thrombolysis each follow-up time point,NIHSS and BI of two groups was improved than that be-fore treatment,the difference was significant (P<0.05);Follow-up for 90 days,the improvement of NIHSS in rtPA group was better than that of rtPA combined with urokinase group,but there was no significant difference (P>0.05).There was no significant difference on the safety and efficacy between the two groups (P>0.05). Conclusion For patients with acute cerebral infarction and no contraindications onset within 6 hours,the efficacy and safety of rtPA combined with uroki-nase is similar to urokinase thrombolytic.关键词
急性脑梗死/静脉溶栓/重组人组织纤溶酶原激活物/尿激酶/时间窗Key words
Acute cerebral infarction/Thrombolysis/Recombinant tissue plasminogen/Urokinase/Time window分类
医药卫生
